Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR)

Bachy Emmanuel; Fox Christopher P.; Arcaini Luca; Hernandez-Ilizaliturri Francisco J.; Howlett Susannah; Snedecor Sonya J.; Franek Jacob; Zaidi Omer; Tabah Ashley

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR)

【24h】

Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR)

机译：系统疗法对复发/难治性惰性非霍奇金淋巴瘤的功效（R / R INHL）：系统文献综述（SLR）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共4页
作者
Bachy Emmanuel; Fox Christopher P.; Arcaini Luca; Hernandez-Ilizaliturri Francisco J.; Howlett Susannah; Snedecor Sonya J.; Franek Jacob; Zaidi Omer; Tabah Ashley;
展开▼
作者单位

Univ Claude Bernard Lyon 1 CHU Lyon Sud Dept Hematol Hosp Civils Lyon Pierre Benite France;

Nottingham Univ Hosp NHS Trust Nottingham England;

Univ Pavia Fdn IRCCS Policlin San Matteo Pavia Italy;

Roswell Pk Comprehens Canc Ctr Buffalo NY USA;

Celgene Corp Summit NJ USA;

Pharmerit Int Bethesda MD USA;

Pharmerit Int Bethesda MD USA;

Pharmerit Int Bethesda MD USA;

Celgene Corp Summit NJ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR) [J] . Bachy Emmanuel, Fox Christopher P., Arcaini Luca, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：系统疗法对复发/难治性惰性非霍奇金淋巴瘤的功效（R / R INHL）：系统文献综述（SLR）
2. Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study [J] . Matsumoto Yosuke, Kobayashi Tsutomu, Shimura Yuji, International journal of hematology . 2019,第1期

机译：用于复发或难治性惰性B细胞非霍奇金淋巴瘤和地幔细胞淋巴瘤的rituximab，Bendamustine和地塞米松化学疗法：多中心二期研究
3. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. [J] . Nagai H, Ogura M, Kusumoto S, European Journal of Haematology . 2011,第2期

机译：克拉屈滨联合利妥昔单抗（R-2-CdA）治疗是复发性或难治性惰性B细胞非霍奇金淋巴瘤的有效挽救疗法。
4. An SLR-Tool: Search Process in Practice : A tool to conduct and manage Systematic Literature Review (SLR) [C] . Andreas Hinderks, Francisco José, Domínguez Mayo, International Conference on Software Engineering: Companion Proceedings . 2020

机译：SLR-Tool：在实践中搜索过程：进行系统文献评论的工具（SLR）
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkins lymphoma [O] . F Buchegger, C Antonescu, A Bischof Delaloye, 2006

机译：131I-tositumomab治疗后复发或难治性惰性非霍奇金淋巴瘤的长期完全缓解
7. PSY74 The Economic And Humanistic Burden Of Relapsed/Refractory (R/R) Indolent Non-Indolent Non-Hodgkin’s Lymphoma (Inhl): An Evidence Gap Analysis [O] . Leinwand B, Brown J, Rai K, 2014

机译：PSY74复发/难治性（R / R）惰性，非惰性，非霍奇金淋巴瘤（Inhl）的经济和人文负担：证据差距分析

Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR)

著录项

相似文献

相关主题

期刊订阅